Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EPS (Weighted Average and Diluted) (2022 - 2025)

Zentalis Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.49 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.49 for Q4 2025, up 25.76% from a year ago — trailing twelve months through Dec 2025 was -$1.9 (up 18.1% YoY), and the annual figure for FY2025 was -$1.91, up 18.03%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.49 at Zentalis Pharmaceuticals, down from -$0.37 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ZNTL hit a ceiling of $0.14 in Q1 2024 and a floor of -$1.85 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.81 (2023), compared with a mean of -$0.83.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 113.08% in 2024 and later crashed 578.57% in 2025.
  • Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.92 in 2022, then increased by 9.78% to -$0.83 in 2023, then grew by 20.48% to -$0.66 in 2024, then grew by 25.76% to -$0.49 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.49 (Q4 2025), -$0.37 (Q3 2025), and -$0.37 (Q2 2025) per Business Quant data.